Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESPOND: Nusinersen in SMA Patients Previously Treated With Onasemnogene Abeparvovec
NCT04488133Phase 4Completed
- Sponsor
- Biogen
- Start
- Jan 2021
- Primary completion
- Oct 2025
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 5
01
Overview
A Phase 4 trial of nusinersen in spinal muscular atrophy (SMA), sponsored by Biogen. Started Jan 2021; status: completed.
02
Drugs
nusinersen
03
Conditions
spinal muscular atrophy (SMA)
Beyond the preview
Go deeper on NCT04488133.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04488133.